| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0049-3848(97)00091-1 |
| P698 | PubMed publication ID | 9253797 |
| P2093 | author name string | Handley DA | |
| Hughes TE | |||
| P2860 | cites work | Fibrinogen titer as an indicator of physiologic stability | Q79444226 |
| Interactions of prostaglandin E1, bradykinin and histamine and the increase of plasma fibrinogen in rats | Q93664520 | ||
| Ciliary neurotrophic factor induces acute-phase protein expression in hepatocytes | Q28180769 | ||
| Fibrinogen and fibrin | Q28267332 | ||
| Interaction of a liver-specific nuclear factor with the fibrinogen and alpha 1-antitrypsin promoters | Q28299313 | ||
| The acute phase protein response in patients receiving subcutaneous IL-6. | Q33488374 | ||
| Anticoagulant therapy with ancrod | Q33493132 | ||
| Exercise, fibrinogen, and other risk factors for ischaemic heart disease. Caerphilly Prospective Heart Disease Study | Q33612289 | ||
| Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study | Q33612628 | ||
| Metabolism of plasminogen in healthy subjects: effect of tranexamic acid | Q34070053 | ||
| Differential effects of insulin deficiency on albumin and fibrinogen synthesis in humans | Q34197587 | ||
| On the pharmacology of bromelain: an update with special regard to animal studies on dose-dependent effects | Q34227752 | ||
| Stimulation of fibrinogen synthesis in cultured rat hepatocytes by fibrinogen degradation product fragment D | Q34318981 | ||
| Fibrinogen: a possible link between social class and coronary heart disease | Q34488611 | ||
| Interleukin-6-Producing Pheochromocytoma | Q34592873 | ||
| Tumor necrosis factor (TNF) is induced in mice by Candida albicans: role of TNF in fibrinogen increase. | Q35103118 | ||
| Fibrinogen‐ and Fibrin‐Degradation Products during Fibrinolytic Therapya | Q35224530 | ||
| Kinetic modeling and mathematical analysis indicate that acute phase gene expression in Hep 3B cells is regulated by both transcriptional and posttranscriptional mechanisms | Q35553679 | ||
| Drugs affecting plasma fibrinogen levels | Q36067954 | ||
| Oligospecificity of the cellular adhesion receptor Mac-1 encompasses an inducible recognition specificity for fibrinogen | Q36219687 | ||
| Supporting role of the adrenal cortex in the induction of hyperfibrinogenemia | Q68575743 | ||
| Effect of chlorophenoxyisobutyric acid (CPIB) on fat-mobilizing lipolysis and cyclic AMP levels in rat epididymal fat | Q68658391 | ||
| Differential effects of endotoxin and fibrinogen degradation products (FDPS) on liver synthesis of fibrinogen and albumin: evidence for the involvement of a novel monokine in the stimulation of fibrinogen synthesis induced by FDPS | Q68658526 | ||
| Fate of fibrinogen in human arterial intima | Q68735946 | ||
| Acute changes in atherogenic and thrombogenic factors with cessation of smoking | Q68752290 | ||
| Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study | Q68979773 | ||
| Induction of rat acute-phase proteins by interleukin 6 in vivo | Q69028903 | ||
| Abstention from chronic cigarette smoking normalizes blood rheology | Q69051619 | ||
| Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis | Q69354510 | ||
| Plasma fibrinogen levels as an independent indicator of severity of coronary atherosclerosis | Q69662969 | ||
| Changes in hemostatic and fibrinolytic proteins in patients receiving L-asparaginase therapy | Q69672924 | ||
| Fibrinogen and pentoxifylline | Q69731927 | ||
| Anti-inflammatory and immuno-modulatory effects of novel retinoid-like 2,4,6,8-nonatetraenoic acids (NTA) in adjuvant-induced arthritis | Q69767525 | ||
| Dietary supplementation with low-dose fish oils lowers fibrinogen levels: a randomized, double-blind controlled study | Q69770567 | ||
| Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study | Q69886150 | ||
| Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease | Q69908116 | ||
| Therapeutic defibrination in the treatment of thrombotic disease | Q70082989 | ||
| Anticoagulant therapy with a purified fraction of Malayan pit viper venom | Q70082992 | ||
| Chronic blood hyperviscosity in subjects with acute stroke, transient ischemic attack, and risk factors for stroke | Q70116341 | ||
| Endogenous forms of fibrinogen in Hep G2 cells | Q70184828 | ||
| Lovastatin therapy in heterozygous familial hypercholesterolaemic patients: effect on blood rheology and fibrinogen levels | Q70222803 | ||
| Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs | Q70372299 | ||
| Metabolism and distribution of fibrinogen. I. Fibrinogen turnover in physiological conditions in humans | Q70459964 | ||
| Effects of long term administration of ticlopidine on platelet function and hemostatic variables | Q70709121 | ||
| Genetic variation at the beta-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction. The ECTIM Study | Q70731158 | ||
| Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study | Q70743335 | ||
| Physiological increments in plasma insulin concentrations have selective and different effects on synthesis of hepatic proteins in normal humans | Q70767530 | ||
| Studies of the clinical pharmacology and therapeutic efficacy of pentoxifylline in peripheral obstructive arterial disease | Q70795394 | ||
| Fibrinogen catabolism in patients with type II and type IV hyperlipidemia. Effect of dietary and clofibrate treatment on laboratory findings | Q70966885 | ||
| Sensitivity of experimental venous and arterial thrombosis and bleeding to ancrod-induced defibrinogenation | Q71569377 | ||
| Whole-body protein turnover and hepatic protein synthesis are increased by vaccination in man | Q71572356 | ||
| Stimulation of fibrinogen biosynthesis by fibrinogen fragments D and E | Q71679043 | ||
| In situ hybridization of interleukin 6 in diabetic nephropathy | Q71736925 | ||
| The effect of WSEWS pentapeptide and WSEWS-specific monoclonal antibodies on constitutive and IL-6 induced acute-phase protein production by a human hepatoma cell line, HEPG-2 | Q71819318 | ||
| Enhancement of interleukin-6 production by fibrinogen degradation product D in human peripheral monocytes and perfused murine liver | Q71947503 | ||
| Fibrinogen and Silent Atherosclerosis in Subjects With Cardiovascular Risk Factors | Q72049303 | ||
| Fibrinogen and factor VIII, but not factor VII, are associated with measures of subclinical cardiovascular disease in the elderly. Results from The Cardiovascular Health Study | Q72049307 | ||
| Free fatty acidemia as an inducer of systemic hyperfibrinogenemia and fibrinolytic inhibition | Q72088606 | ||
| Relationship of cigarette smoking and snuff dipping to plasma fibrinogen, fibrinolytic variables and serum insulin. The Northern Sweden MONICA Study | Q72250137 | ||
| Fibrinogen after coronary angioplasty as a risk factor for restenosis | Q72331374 | ||
| Experimental and control systems studies of plasma fibrinogen regulation in rabbits | Q72366160 | ||
| Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1 beta, IL-6 and plasminogen activator inhibitors from monocytes in vitro | Q72490514 | ||
| The Comparison of the Antithrombotic Action of the Thrombin-like Fraction of Malayan Pit Viper Venom and Heparin | Q72531035 | ||
| The fibrinolytic response to stanozolol in normal subjects | Q72650920 | ||
| Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men | Q72690028 | ||
| Fibrinogen, a vascular risk factor: a simple marker or a real cause of vascular lesion? | Q72887270 | ||
| EFFECTS OF EPSILON AMINO CAPROIC ACID (EACA) ON SURVIVAL OF FIBRINOGEN I-131 AND ON FIBRINOLYTIC AND COAGULATION FACTORS IN DOGS | Q76721137 | ||
| PHENFORMIN IN RHEUMATOID ARTHRITIS. A FIBRINOLYTIC APPROACH | Q77153924 | ||
| A long-term study of the effects of celiprolol on blood pressure and lipid-associated risk factors. | Q51624160 | ||
| Hypertriglyceridaemia and hypercoagulability | Q51647241 | ||
| Impaired immune and acute-phase responses in interleukin-6-deficient mice. | Q52514391 | ||
| Fibrinogen assembly and secretion. Role of intrachain disulfide loops. | Q52522711 | ||
| Fibrinogen fragments X, Y, D and E increase levels of plasma fibrinogen and liver mRNAs coding for fibrinogen polypeptides in rats. | Q54212569 | ||
| Effect of clofibrate on blood viscosity in intermittent claudication. | Q54215867 | ||
| Secretion of biologically active recombinant fibrinogen by yeast | Q56766048 | ||
| Control of fibrinogen biosynthesis: The role of free fatty acid | Q56864020 | ||
| A new hepatocyte stimulating factor: cardiotrophin-1 (CT-1) | Q62658940 | ||
| Studies on the structure and regulation of the human hepatic interleukin-6 receptor | Q62658978 | ||
| Plasma Cofactors of Platelet Function: Correlation with Diabetic Retinopathy and Hemoglobins Ala-c | Q66876851 | ||
| Phenformin and ethyloestrenol in recurrent venous thrombosis | Q67281101 | ||
| The sulphite precipitation method for fibrinogen measurement; Its use on small samples in the presence of fibrinogen degradation products | Q67438379 | ||
| Hyperfibrinogenemia. An important risk factor for vascular complications in diabetes | Q67574961 | ||
| Simultaneous expression and regulation of G-CSF and IL-6 mRNA in adherent human monocytes and fibroblasts | Q67691033 | ||
| Free fatty acids and albumin as mediators of thrombin-stimulated fibrinogen synthesis | Q67779402 | ||
| Fibrinogen association with human monocytes: evidence for constitutive expression of fibrinogen receptors and for involvement of Mac-1 (CD18, CR3) in the binding | Q67946977 | ||
| Lovastatin therapy in hypercholesterolemia: effect on fibrinogen, hemorrheologic parameters, platelet activity, and red blood cell morphology | Q67957688 | ||
| Maxepa versus bezafibrate in hyperlipidemic cardiac transplant recipients | Q67967130 | ||
| Effects of long-term treatment with lovastatin on the clotting system and blood platelets | Q68118566 | ||
| Fibrinogen: the plot thickens | Q68128603 | ||
| Blood viscosity, lipoproteins, and cardiovascular risk | Q68134063 | ||
| Influence of Etofibrate on plasma fibrinogen and plasminogen concentrations in patients with different forms of primary hyperlipoproteinemia | Q68229323 | ||
| Abnormalities of blood rheology in familial hypercholesterolaemia: effects of treatment | Q68385162 | ||
| Influence of dietary trans,trans-linoleate on hematologic and hemostatic properties of rat blood | Q68450954 | ||
| Effect of short-term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients | Q68462976 | ||
| The role of plasma free fatty acids in the elevation of plasma cholesterol and phospholipids produced by adrenaline | Q68562213 | ||
| Regulation of fibrinogen synthesis by plasmin-derived fragments of fibrinogen and fibrin: an indirect feedback pathway | Q36285065 | ||
| Interleukin-6 and the acute phase response | Q36559880 | ||
| Pharmacological enhancement of fibrinolytic activity and 125I-fibrinogen survival | Q36624101 | ||
| An evaluation of the heat precipitation method for plasma fibrinogen estimation | Q36632977 | ||
| Dietary prevention of coronary heart disease. Effect of dietary fats on arterial thrombosis | Q36716421 | ||
| Functional inhibition of hematopoietic and neurotrophic cytokines by blocking the interleukin 6 signal transducer gp130 | Q37304521 | ||
| CD11c/CD18 on neutrophils recognizes a domain at the N terminus of the A alpha chain of fibrinogen | Q37393021 | ||
| Hepatic acute phase reaction in vivo and in vitro | Q38198677 | ||
| Characterization of the IL-6 Responsive Elements in the γ Fibrinogen Gene Promoter | Q38290358 | ||
| Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication | Q39492304 | ||
| Subcutaneous ancrod in prevention of deep-vein thrombosis after operation for fractured neck of femur | Q39507477 | ||
| Controlled Defibrination in the Treatment of Peripheral Vascular Disease | Q39717843 | ||
| Improvement in experimental vascular graft patency by controlled defibrinogenation | Q39798794 | ||
| On the therapy of disturbances of blood fluidity | Q39826533 | ||
| Hormonal regulation of fibrinogen synthesis in cultured hepatocytes | Q40135892 | ||
| Fat metabolism, the fibrinogen/fibrinolytic system and blood flow: new potentials for the pharmacological treatment of coronary heart disease | Q40317000 | ||
| The effect of L-asparaginase of plasma coagulation factors in acute lymphoblastic leukemia | Q40500288 | ||
| How does ticlopidine treatment lower plasma fibrinogen? | Q40650319 | ||
| Effect of fibrinogenolytic products D and E on fibrinogen and albumin synthesis in the rat. | Q40682983 | ||
| The relation among stress, adrenalin, interleukin 6 and acute phase proteins in the rat | Q40757514 | ||
| Pharmacological control of hypertriglyceridemia. | Q40842144 | ||
| Liver nonparenchymal cells are stimulated to provide interleukin 6 for induction of the hepatic acute-phase response in endotoxemia but not in remote localized inflammation | Q41142307 | ||
| Characterization of the 5'-flanking region of the gene for the gamma chain of human fibrinogen | Q41269343 | ||
| The role of amino-terminal disulfide bonds in the structure and assembly of human fibrinogen | Q41577729 | ||
| Fatty acids, fibrinogen and blood flow: a general mechanism for hyperfibrinogenemia and its pathologic consequences | Q41614303 | ||
| Up-regulation of the interleukin-6-signal transducing protein (gp130) by interleukin-6 and dexamethasone in HepG2 cells | Q41640170 | ||
| Improvement of the flow properties of blood: a new therapeutical approach in occlusive arterial disease | Q41776852 | ||
| Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients | Q41875844 | ||
| Biosynthesis, assembly and secretion of fibrinogen in cultured rat hepatocytes. | Q41910278 | ||
| The human beta fibrinogen promoter contains a hepatocyte nuclear factor 1-dependent interleukin-6-responsive element | Q42153397 | ||
| Regulation of interleukin-6 release by human thyrocytes | Q42480796 | ||
| Routine measurement of fibrinogen concentration | Q43151379 | ||
| The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. PLAT Study Group. Progetto Lombardo Atero-Trombosi (PLAT) Study Group | Q43586287 | ||
| Determinants of plasma fibrinogen: relation to body weight, waist-to-hip ratio, smoking, alcohol, age, and sex. Results from the second MONICA Augsburg survey 1989-1990 | Q43613193 | ||
| Fibrinolytic treatment of rheumatoid arthritis with phenformin plus ethyloestrenol | Q43752784 | ||
| A phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkins lymphoma | Q43866468 | ||
| Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies | Q43950275 | ||
| The Effect of Linolenic Acid Orally on Platelet Adhesiveness and Fibrinogen Concentration | Q44042115 | ||
| Changes in blood lipids and fibrinogen with a note on safety in a long term study on the effects of n-3 fatty acids in subjects receiving fish oil supplements and followed for seven years | Q44132801 | ||
| Low-affinity interaction of fibrinogen carboxy-gamma terminus with human monocytes induces an oxidative burst and modulates effector functions | Q44259648 | ||
| Improvement of silent myocardial ischaemia and reduction of plasma fibrinogen during nisoldipine therapy in occult coronary arterial disease | Q44475158 | ||
| Risk factors for cardiovascular disease in IDDM. A study of identical twins | Q44652574 | ||
| Effects of niceritrol on levels of serum lipids, lipoprotein(a), and fibrinogen in patients with primary hypercholesterolemia | Q44773230 | ||
| Fibrinogen Catabolism: Kinetics of Catabolism following Sudden Elevation of the Pool with Exogenous Fibrinogen | Q44807381 | ||
| Sustained correction of the bleeding time in an afibrinogenaemic patient after infusion of fresh frozen plasma | Q45879451 | ||
| Differences between plasma viscosity and proteins of types 1 and 2 diabetic Africans in early phase of diabetes | Q46383544 | ||
| A New Approach in the Treatment of Peripheral Arterial Occlusions: Defibrination With Arvin | Q47882233 | ||
| Cloning and characterization of a cDNA for the B beta chain of rat fibrinogen: evolutionary conservation of translated and 3'-untranslated sequences | Q48293934 | ||
| Treatment of Raynaud's phenomenon by fibrinolytic enhancement | Q48581900 | ||
| Clinical, haemodynamic, rheological, and biochemical findings in 126 patients with intermittent claudication. | Q50289871 | ||
| Plasma fibrinogen in NIDDM: the Rotterdam study. | Q51021585 | ||
| Fibrinogen plasma levels as a marker of thrombin activation in diabetes. | Q51596275 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 1-36 | |
| P577 | publication date | 1997-07-01 | |
| P1433 | published in | Thrombosis Research | Q15758741 |
| P1476 | title | Pharmacological approaches and strategies for therapeutic modulation of fibrinogen | |
| P478 | volume | 87 |
| Q29544400 | Alcohol at Moderate Levels Decreases Fibrinogen Expression In Vivo and In Vitro |
| Q73539166 | Alteration of the fibrinogen molecule and its phosphorylation state in myocardial infarction patients undergoing thrombolytic treatment |
| Q36608415 | Beneficial effects of the addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions. |
| Q50196870 | Bromelain and cardiovascular risk factors in diabetes: An exploratory randomized, placebo controlled, double blind clinical trial |
| Q92710708 | Fibrin(ogen) in human disease: both friend and foe |
| Q73515164 | Fibrinogen fractions in the third trimester of pregnancy and in puerperium |
| Q47286296 | Postoperative plasma interleukin-6 in patients with renal cancer correlates with C-reactive protein but not with total fibrinogen or with high molecular weight fibrinogen fraction |
Search more.